Maze Therapeutics Q3 2026 Results: Net Loss of $48M, Loss Widens
Maze Therapeutics is a clinical-stage biopharmaceutical company focused on its Compass platform and lead therapeutic candidates MZE829 and MZE782. As of November 4, 2026, the company had 54,683,345 shares of common stock outstanding and continues to report significant operating losses with no product revenue generated to date.
- Key figure
- Net loss $48M